Gwendolyn Wu
Senior Reporter | LinkedInGwendolyn Wu is a senior reporter at BioPharma Dive covering biotech startups, venture capital, IPOs and the ecosystem that supports them. She was selected as the 2024 McAllister Editorial Fellow by SIIA in recognition for her work on a series of stories examining the world’s first CRISPR medicine. Previously, she authored Bay Briefing, the San Francisco Chronicle’s flagship weekday newsletter, and covered COVID-19 and the business of healthcare for the Houston Chronicle. Outside of the newsroom, Gwendolyn teaches at the California Scholastic Press Association summer workshop for high school journalists, and has led student and early career programs for the Asian American Journalists Association. She has degrees in history and sociology from the University of California at Santa Barbara.
468 articles by Gwendolyn Wu
-
An ‘off-the-shelf’ CAR-T therapy from Adicet shows promise against lupus
Sept. 28, 2026 -
This week in charts: Novo’s rise and fall and AI biotechs’ big haul
Sept. 25, 2026 -
RNAi drug specialist ADARx raises $446M IPO
Sept. 24, 2026 -
Enveda, an AI drugmaker, banks $311M in venture funding
Sept. 23, 2026 -
Amgen reports a Phase 3 win with Sjögren’s drug candidate
Sept. 22, 2026 -
Beacon eye gene therapy hits mark in late-stage study
Sept. 21, 2026 -
Electra amasses $350M in biotech’s latest big IPO
Sept. 17, 2026 -
Roche, Dualitas team up to find bispecific drugs for immune diseases
Sept. 17, 2026 -
Sling banks $123M for an experimental thyroid eye disease pill
Sept. 16, 2026 -
FDA launches pilot program to speed up early US drug research
Sept. 15, 2026 -
Kura spins diabetes work into a Lilly-backed biotech startup
Sept. 9, 2026 -
A new immuno-oncology play raises $225M for a next-generation drug
Sept. 9, 2026 -
Moonwalk reloads with $70M and new RNAi prospects for obesity
Sept. 8, 2026 -
BrainChild hauls in $116M to make cell therapies for childhood brain cancers
Sept. 8, 2026 -
This week in charts: China deals, stock flatlines and Lilly’s M&A spree
Sept. 4, 2026 -
An AI drug specialist zeroes in on rare forms of obesity
Sept. 3, 2026 -
Alumis’ TYK2 drug fails in key lupus study
Sept. 1, 2026 -
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
Aug. 31, 2026 -
FDA green lights Priovant drug for rare skin disease
Aug. 28, 2026 -
Revolution drug heralded as a pancreatic cancer breakthrough cleared by FDA
Aug. 26, 2026 -
Young startups miss out on biotech venture funding rebound, MassBio says
Aug. 25, 2026 -
Cellares, a cell therapy manufacturing specialist, to lay off 100 employees
Aug. 24, 2026 -
Slate, Fulcrum to combine in reverse merger
Aug. 17, 2026 -
Boulevard starts up with $65M to pursue targeted autoimmune drugs
Aug. 12, 2026 -
Chasing Dupixent, a biotech aims to make better antibody drugs for eczema
Aug. 11, 2026
